These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 19513541

  • 1. A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.
    Zou ZQ, Zhang XH, Wang F, Shen QJ, Xu J, Zhang LN, Xing WH, Zhuo RJ, Li D.
    Int J Mol Med; 2009 Jul; 24(1):97-101. PubMed ID: 19513541
    [Abstract] [Full Text] [Related]

  • 2. Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
    Moreira-Leite FF, Harrison LR, Mironov A, Roberts RA, Dive C.
    J Thorac Oncol; 2010 Jun; 5(6):765-77. PubMed ID: 20421816
    [Abstract] [Full Text] [Related]

  • 3. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S.
    Clin Cancer Res; 2011 Apr 15; 17(8):2260-9. PubMed ID: 21220474
    [Abstract] [Full Text] [Related]

  • 4. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
    Huang Y, Chen Y, Mei Q, Chen Y, Yu S, Xia S.
    Oncol Rep; 2013 Jun 15; 29(6):2486-92. PubMed ID: 23525575
    [Abstract] [Full Text] [Related]

  • 5. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
    Chiarini F, Falà F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM.
    Cancer Res; 2009 Apr 15; 69(8):3520-8. PubMed ID: 19351820
    [Abstract] [Full Text] [Related]

  • 6. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.
    Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L, Knight ZA, Shokat KM, Azar N, Viguié F, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D.
    Leukemia; 2008 Sep 15; 22(9):1698-706. PubMed ID: 18548104
    [Abstract] [Full Text] [Related]

  • 7. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
    Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA.
    Cancer Res; 2007 Sep 01; 67(17):7960-5. PubMed ID: 17804702
    [Abstract] [Full Text] [Related]

  • 8. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells.
    Zou ZQ, Zhang LN, Wang F, Bellenger J, Shen YZ, Zhang XH.
    Mol Med Rep; 2012 Feb 01; 5(2):503-8. PubMed ID: 22101421
    [Abstract] [Full Text] [Related]

  • 9. Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
    Chaisuparat R, Hu J, Jham BC, Knight ZA, Shokat KM, Montaner S.
    Cancer Res; 2008 Oct 15; 68(20):8361-8. PubMed ID: 18922908
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
    López-Fauqued M, Gil R, Grueso J, Hernandez-Losa J, Pujol A, Moliné T, Recio JA.
    Int J Cancer; 2010 Apr 01; 126(7):1549-61. PubMed ID: 19810100
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.
    Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, Chen J, Rafidi K, Feng Z, Nickel J, Engebretsen J, Hallin J, Blasina A, Zhang E, Nguyen L, Sun M, Vogt PK, McHarg A, Cheng H, Christensen JG, Kan JL, Bagrodia S.
    Mol Cancer Ther; 2011 Nov 01; 10(11):2189-99. PubMed ID: 21750219
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells.
    Azzariti A, Porcelli L, Gatti G, Nicolin A, Paradiso A.
    Biochem Pharmacol; 2008 Mar 01; 75(5):1035-44. PubMed ID: 18191814
    [Abstract] [Full Text] [Related]

  • 18. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells.
    Lee H, Kim SJ, Jung KH, Son MK, Yan HH, Hong S, Hong SS.
    Oncol Rep; 2013 Aug 01; 30(2):863-9. PubMed ID: 23708425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.